Posted by Michael Wonder on 15 Nov 2022
Enhertu recommended for approval in the EU by CHMP for patients with previously treated HER2 positive advanced gastric cancer
14 November 2022 - Based on DESTINY-Gastric02, which showed Daiichi Sankyo and AstraZeneca’s Enhertu demonstrated clinically meaningful efficacy and DESTINY-Gastric01, which showed improved overall survival compared to chemotherapy.
Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union as a monotherapy for the treatment of adult patients with advanced HER2 positive gastric or gastro-oesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.
